Jazz Pharmaceuticals Announces Offering of $500 Million of Exchangeable Senior Notes due 2024 DUBLIN

Jazz Pharmaceuticals Announces Offering of $500 Million of Exchangeable Senior Notes due 2024

DUBLIN, Aug. 17, 2017 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced an offering by Jazz Investments I Limited, its wholly-owned

subsidiary (the Issuer ), of $500 million aggregate principal amount of exchangeable senior notes due 2024 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the

Securities Act ). The Issuer has also granted the initial purchasers a 13-day option to purchase up to an additional $75 million aggregate principal amount of notes.

The notes will be exchangeable under certain circumstances for cash, ordinary shares of Jazz Pharmaceuticals plc ( ordinary shares ), or a

combination thereof. The Issuer s obligations under the notes will be fully and unconditionally guaranteed on a senior unsecured basis by Jazz Pharmaceuticals plc and will rank pari passu in right of payment with the Issuer s existing

1.875% exchangeable senior notes due 2021.

Jazz Pharmaceuticals plc intends to use the net proceeds from this offering to repay all or a substantial

portion of $500 million of outstanding borrowings under its revolving credit facility. Any remaining net proceeds will be used for general corporate purposes, including potential business development activities.

None of the notes, the guarantee or the ordinary shares issuable upon exchange of the notes, if any, has been registered under the Securities Act or the

securities laws of any other jurisdiction, and such securities may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any notes, the guarantee or ordinary shares, nor

shall there be any sale of notes, the guarantee or ordinary shares in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or

jurisdiction. The notes will be offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients

lives by identifying, developing and commercializing meaningful products that address unmet medical needs. Jazz Pharmaceuticals has a diverse portfolio of products and product candidates, with a focus in the areas of sleep and

hematology/oncology. In these areas, Jazz Pharmaceuticals markets Xyrem (sodium oxybate) oral solution, Erwinaze

(asparaginase Erwinia chrysanthemi), Defitelio (defibrotide sodium) and Vyxeos (daunorubicin and cytarabine) liposome for injection in the United States and markets Erwinase and Defitelio (defibrotide) in countries outside the United States.

Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not

limited to, all statements related to the offering of the notes, the guarantee and ordinary shares, including the closing thereof, and the expected use of the net proceeds from the offering. These forward-looking statements are based on Jazz

Pharmaceuticals current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements

as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the satisfaction of closing conditions related to the offering and market

risks. These and other risks and uncertainties relating to Jazz Pharmaceuticals and its business can be found under the caption Risk Factors and elsewhere in Jazz Pharmaceuticals plc s Securities and Exchange Commission filings and

reports (Commission File No. 001-33500), including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 and future filings and reports by Jazz Pharmaceuticals plc. Jazz Pharmaceuticals undertakes no duty or obligation to

update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations.

Jazz Pharmaceuticals Contacts: